Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

Neonatal Care Unit receives donation to expand capacity
2015-10-28

  

With the best care and technology available,
the survival rate of premature
babies is about 85%. The neonatal intensive
care unit at the Universitas hospital can now
expand its capacity thanks to a donation of
R1 million by the Discovery fund.
From the left is Prof André Venter.
Head: Department of Paediatrics and
Child Health at the UFS, and mrs Ruth Lewin,
Head: Corporate Sustainability at Discovery. 

The smallest people need the greatest care. This care is being provided by the neonatal unit in the Children’s Wing of the Universitas Hospital. This project of the University of the Free State (UFS), under the leadership of Prof Andre Venter, has led to several miracles regarding child health since its inception.

Now, thanks to a donation of R1 million rand from the Discovery fund, this unit can expand its capacity and treat more premature babies.

About 14% of babies in South Africa are born before the 37th week of pregnancy. These babies are born with a very low birth weight, and are in need of critical care. The neonatal intensive-care unit at Universitas Hospital is currently equipped to take care of about 14 premature babies at a time, from birth to discharge. However, because of the high incidence of premature births in the hospital’s service area, the unit needs about 45 beds.

The aim of the Children’s Wing Project is to expand the neonatal intensive-care unit in order to meet the demands of the hospital’s service area, which reaches as far as the Southern Cape. The Discovery Fund recently donated R1 million to the project, which will be used to expand the capacity of the neonatal intensive-care unit.

“With the best care and technology available, the survival rate of premature babies is about 85%. Without this, half of all premature babies would die,” says Prof Venter, Head: Department of Paediatrics and Child Health at the UFS.

“This is the reason why private and public partnerships, such as the one with Discovery, are essential to make specialised services available to the most vulnerable people. Discovery has made a significant contribution to the project without which we would not have been able to expand the capacity of the unit



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept